125 related articles for article (PubMed ID: 20424934)
1. Concurrent administration of liposomal doxorubicin improves the survival of patients with invasive bladder cancer undergoing hypofractionated accelerated radiotherapy (HypoARC).
Panteliadou M; Touloupidis S; Giatromanolaki A; Pistevou K; Kyrgias G; Tsoutsou P; Kalaitzis C; Koukourakis MI
Med Oncol; 2011 Dec; 28(4):1356-62. PubMed ID: 20424934
[TBL] [Abstract][Full Text] [Related]
2. Radical hypofractionated accelerated radiotherapy with cytoprotection for invasive bladder cancer.
Koukourakis MI; Tsolos C; Touloupidis S
Urology; 2007 Feb; 69(2):245-50. PubMed ID: 17320657
[TBL] [Abstract][Full Text] [Related]
3. Treatment of invasive bladder cancer with conformal hypofractionated accelerated radiotherapy and amifostine (HypoARC).
Panteliadou M; Giatromanolaki A; Touloupidis S; Destouni E; Tsoutsou PG; Pantelis P; Abatzoglou I; Sismanidou K; Koukourakis MI
Urol Oncol; 2012; 30(6):813-20. PubMed ID: 21163674
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer.
Choudhury A; Swindell R; Logue JP; Elliott PA; Livsey JE; Wise M; Symonds P; Wylie JP; Ramani V; Sangar V; Lyons J; Bottomley I; McCaul D; Clarke NW; Kiltie AE; Cowan RA
J Clin Oncol; 2011 Feb; 29(6):733-8. PubMed ID: 21205754
[TBL] [Abstract][Full Text] [Related]
6. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy.
Hagan MP; Winter KA; Kaufman DS; Wajsman Z; Zietman AL; Heney NM; Toonkel LM; Jones CU; Roberts JD; Shipley WU
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):665-72. PubMed ID: 14529770
[TBL] [Abstract][Full Text] [Related]
7. Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients.
Koukourakis MI; Giatromanolaki A; Kouroussis C; Kakolyris S; Sivridis E; Frangiadaki C; Retalis G; Georgoulias V;
Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):144-55. PubMed ID: 11777632
[TBL] [Abstract][Full Text] [Related]
8. Concurrent cisplatin, 5-fluorouracil, leucovorin, and radiotherapy for invasive bladder cancer.
Chen WC; Liaw CC; Chuang CK; Chen MF; Chen CS; Lin PY; Chang PL; Chu SH; Wu CT; Hong JH
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):726-33. PubMed ID: 12788178
[TBL] [Abstract][Full Text] [Related]
9. Hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) combined with vinorelbine and liposomal doxorubicin for locally advanced non-small cell lung cancer (NSCLC).
Tsoutsou PG; Froudarakis ME; Bouros D; Koukourakis MI
Anticancer Res; 2008; 28(2B):1349-54. PubMed ID: 18505077
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802.
Tester W; Caplan R; Heaney J; Venner P; Whittington R; Byhardt R; True L; Shipley W
J Clin Oncol; 1996 Jan; 14(1):119-26. PubMed ID: 8558186
[TBL] [Abstract][Full Text] [Related]
11. Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer.
Maarouf AM; Khalil S; Salem EA; ElAdl M; Nawar N; Zaiton F
BJU Int; 2011 May; 107(10):1605-10. PubMed ID: 20825396
[TBL] [Abstract][Full Text] [Related]
12. Combination transurethral resection, systemic chemotherapy, and pelvic radiotherapy for invasive (T2-T4) bladder cancer unsuitable for cystectomy: a phase I/II Southwestern Oncology Group study.
Einstein AB; Wolf M; Halliday KR; Miller GJ; Hafermann M; Lowe BA; Meyers FJ; Leimert JT; Crawford ED
Urology; 1996 May; 47(5):652-7. PubMed ID: 8650861
[TBL] [Abstract][Full Text] [Related]
13. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control.
Varveris H; Delakas D; Anezinis P; Haldeopoulos D; Mazonakis M; Damilakis J; Metaxaris G; Chondros N; Mavromanolakis E; Daskalopoulos G; Dimitrakopoulos A; Kranidis A
Anticancer Res; 1997; 17(6D):4771-80. PubMed ID: 9494605
[TBL] [Abstract][Full Text] [Related]
14. Muscle-invasive transitional cell carcinoma of the urinary bladder: a population-based study of patterns of care and prognostic factors.
Scrimger RA; Murtha AD; Parliament MB; Venner PM; Hanson J; Houle G; Chetner M
Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):23-30. PubMed ID: 11516847
[TBL] [Abstract][Full Text] [Related]
15. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.
Blick C; Hall P; Pwint T; Al-Terkait F; Crew J; Powles T; Macaulay V; Munro N; Douglas D; Kilbey N; Protheroe A; Chester JD
Cancer; 2012 Aug; 118(16):3920-7. PubMed ID: 22614698
[TBL] [Abstract][Full Text] [Related]
16. The role of combined method in organ-sparing treatment of muscle-invasive bladder cancer recurrences.
Startsev VY
Arch Ital Urol Androl; 2002 Jun; 74(2):54-6. PubMed ID: 12161935
[TBL] [Abstract][Full Text] [Related]
17. Concurrent chemoradiotherapy for clinical stage T2 bladder cancer: report of a single institution.
Peyromaure M; Slama J; Beuzeboc P; Ponvert D; Debré B; Zerbib M
Urology; 2004 Jan; 63(1):73-7. PubMed ID: 14751352
[TBL] [Abstract][Full Text] [Related]
18. Postoperative pelvic hypofractionated accelerated radiotherapy with cytoprotection (HypoARC) for high-risk or recurrent prostate cancer.
Koukourakis MI; Papadopoulou A; Abatzoglou I; Panteliadou M; Sismanidou K; Touloupidis S
Anticancer Res; 2012 Oct; 32(10):4561-8. PubMed ID: 23060587
[TBL] [Abstract][Full Text] [Related]
19. Shifting from hypofractionated to "conventionally" fractionated thoracic radiotherapy: a single institution's 10-year experience in the management of limited-stage small-cell lung cancer using concurrent chemoradiation.
Videtic GM; Truong PT; Dar AR; Yu EW; Stitt LW
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):709-16. PubMed ID: 14529775
[TBL] [Abstract][Full Text] [Related]
20. Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?
Pouessel D; Chevret S; Rolland F; Gravis G; Geoffrois L; Roubaud G; Terrisse S; Boyle H; Chevreau C; Dauba J; Moriceau G; Alexandre I; Deplanque G; Chapelle A; Vauleon E; Colau A; Audenet F; Grellety T; Culine S
Eur J Cancer; 2016 Feb; 54():69-74. PubMed ID: 26724422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
